Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 5/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 13/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5280696 | 1.00 | ADRB2 (0.38) | ADRB2ADRB3ADRB1SMN1; SMN2NPC1 | |
| SCHEMBL5373388 | 0.95 | ADRB2 (0.39) | ADRB2ADRB3ADRB1SMN1; SMN2KDM4E | |
| SCHEMBL5373383 | 0.95 | ADRB2 (0.39) | ADRB2ADRB3ADRB1SMN1; SMN2KDM4E | |
| SCHEMBL5283602 | 0.92 | NPC1 (0.40) | ADRB2ADRB3ADRB1SMN1; SMN2NPC1 | |
| SCHEMBL5283607 | 0.92 | NPC1 (0.40) | ADRB2ADRB3ADRB1SMN1; SMN2NPC1 | |
| SCHEMBL5282937 | 0.92 | ADRB2 (0.40) | ADRB2ADRB3ADRB1SMN1; SMN2KDM4E | |
| SCHEMBL5282944 | 0.92 | ADRB2 (0.40) | ADRB2ADRB3ADRB1SMN1; SMN2KDM4E | |
| SCHEMBL5431423 | 0.92 | MEN1 (0.39) | ADRB2ADRB3ADRB1NPC1MAPT | |
| SCHEMBL5288433 | 0.90 | ADRB3 (0.45) | ADRB2ADRB3ADRB1SMN1; SMN2KDM4E | |
| SCHEMBL5288452 | 0.90 | ADRB3 (0.45) | ADRB2ADRB3ADRB1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1497261-B1 | PHENETHANOLAMINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2007-12-19 | — | — | EP | disclosed |
| US-7271197-B2 | Phenethanolamine derivatives | GLAXO GROUP LIMITED (GB) | 2007-09-18 | — | — | US | disclosed |
| US-20050256201-A1 | Phenethanolamine derivatives | GLAXO GROUP LIMITED | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256201-A1 | Phenethanolamine derivatives | PNMT, PHOSPHO1, NAPEPLD | ADRB2 85/4885ADRB3 67/4885ADRB1 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.